Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Cirrhosis, Biliary | 16 | 2024 | 108 | 5.860 |
Why?
|
Hepatitis, Autoimmune | 8 | 2024 | 172 | 3.080 |
Why?
|
Cholangitis | 5 | 2024 | 111 | 2.530 |
Why?
|
Liver Transplantation | 13 | 2024 | 2330 | 2.190 |
Why?
|
Liver Diseases | 7 | 2022 | 1298 | 2.020 |
Why?
|
Cholangitis, Sclerosing | 3 | 2023 | 177 | 1.380 |
Why?
|
End Stage Liver Disease | 5 | 2023 | 352 | 1.370 |
Why?
|
Ursodeoxycholic Acid | 9 | 2024 | 81 | 1.350 |
Why?
|
Waiting Lists | 5 | 2024 | 765 | 1.030 |
Why?
|
Cholagogues and Choleretics | 8 | 2024 | 39 | 1.020 |
Why?
|
Elasticity Imaging Techniques | 6 | 2024 | 392 | 1.020 |
Why?
|
Osteoporosis | 3 | 2019 | 1606 | 0.970 |
Why?
|
Liver Cirrhosis | 10 | 2022 | 1935 | 0.910 |
Why?
|
Cholestasis | 3 | 2023 | 378 | 0.900 |
Why?
|
Carcinoma, Hepatocellular | 5 | 2023 | 2298 | 0.790 |
Why?
|
Autoimmune Diseases | 3 | 2020 | 2244 | 0.640 |
Why?
|
Pruritus | 3 | 2023 | 380 | 0.640 |
Why?
|
Liver Neoplasms | 5 | 2023 | 4320 | 0.620 |
Why?
|
Graft Survival | 5 | 2024 | 3819 | 0.590 |
Why?
|
Bone Density Conservation Agents | 3 | 2019 | 795 | 0.560 |
Why?
|
Liver | 8 | 2024 | 7529 | 0.490 |
Why?
|
Bone Diseases, Metabolic | 1 | 2019 | 409 | 0.490 |
Why?
|
Osteogenesis | 2 | 2019 | 1273 | 0.480 |
Why?
|
Fatigue | 2 | 2019 | 1552 | 0.470 |
Why?
|
Hepatitis | 1 | 2015 | 228 | 0.440 |
Why?
|
Hepatitis C, Chronic | 4 | 2014 | 1032 | 0.410 |
Why?
|
Cystadenocarcinoma | 1 | 2012 | 54 | 0.410 |
Why?
|
Bone Density | 3 | 2019 | 3551 | 0.380 |
Why?
|
Fatty Liver | 3 | 2024 | 790 | 0.380 |
Why?
|
Benzazepines | 1 | 2013 | 310 | 0.360 |
Why?
|
Hyponatremia | 1 | 2013 | 279 | 0.350 |
Why?
|
Receptors, Aryl Hydrocarbon | 2 | 2023 | 220 | 0.340 |
Why?
|
Socioeconomic Factors | 1 | 2023 | 7827 | 0.340 |
Why?
|
Healthcare Disparities | 2 | 2023 | 3358 | 0.320 |
Why?
|
Anthropometry | 1 | 2012 | 1349 | 0.300 |
Why?
|
Hemangioma | 1 | 2012 | 727 | 0.280 |
Why?
|
Aspartate Aminotransferases | 4 | 2020 | 416 | 0.280 |
Why?
|
Ischemia | 1 | 2015 | 1882 | 0.270 |
Why?
|
Gastrointestinal Hemorrhage | 3 | 2018 | 1116 | 0.260 |
Why?
|
Esophageal and Gastric Varices | 2 | 2018 | 208 | 0.250 |
Why?
|
Chenodeoxycholic Acid | 1 | 2024 | 34 | 0.230 |
Why?
|
Osteoporotic Fractures | 2 | 2019 | 411 | 0.230 |
Why?
|
Diphosphonates | 2 | 2019 | 636 | 0.230 |
Why?
|
Bezafibrate | 1 | 2023 | 14 | 0.220 |
Why?
|
Hormone Replacement Therapy | 2 | 2019 | 751 | 0.220 |
Why?
|
Antipruritics | 1 | 2023 | 31 | 0.210 |
Why?
|
Alanine Transaminase | 3 | 2015 | 603 | 0.210 |
Why?
|
Humans | 52 | 2024 | 761504 | 0.210 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2022 | 128 | 0.190 |
Why?
|
Adenoma | 1 | 2012 | 2160 | 0.190 |
Why?
|
Chalcones | 1 | 2021 | 30 | 0.190 |
Why?
|
PPAR delta | 1 | 2021 | 40 | 0.180 |
Why?
|
Alkaline Phosphatase | 5 | 2024 | 864 | 0.180 |
Why?
|
Propionates | 1 | 2021 | 183 | 0.170 |
Why?
|
Hepatitis B, Chronic | 2 | 2014 | 410 | 0.170 |
Why?
|
PPAR alpha | 1 | 2021 | 175 | 0.170 |
Why?
|
Databases, Factual | 3 | 2024 | 7967 | 0.160 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 857 | 0.150 |
Why?
|
Th17 Cells | 2 | 2023 | 794 | 0.150 |
Why?
|
Chylous Ascites | 1 | 2017 | 21 | 0.150 |
Why?
|
Apyrase | 1 | 2020 | 373 | 0.150 |
Why?
|
Retrospective Studies | 15 | 2024 | 80636 | 0.140 |
Why?
|
Risk Factors | 6 | 2023 | 74206 | 0.140 |
Why?
|
Drug Approval | 1 | 2024 | 814 | 0.140 |
Why?
|
Balloon Occlusion | 1 | 2017 | 125 | 0.140 |
Why?
|
Educational Status | 1 | 2023 | 2522 | 0.130 |
Why?
|
Liver Function Tests | 3 | 2015 | 523 | 0.130 |
Why?
|
Recurrence | 3 | 2024 | 8465 | 0.130 |
Why?
|
Disease Progression | 4 | 2024 | 13506 | 0.120 |
Why?
|
Varicose Veins | 1 | 2017 | 155 | 0.120 |
Why?
|
Bone Resorption | 1 | 2019 | 723 | 0.120 |
Why?
|
Bilirubin | 4 | 2021 | 436 | 0.120 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 1136 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2023 | 10209 | 0.110 |
Why?
|
Nucleosides | 1 | 2014 | 131 | 0.110 |
Why?
|
Lipoproteins | 1 | 2019 | 881 | 0.110 |
Why?
|
Ascites | 1 | 2015 | 338 | 0.110 |
Why?
|
Cholestasis, Intrahepatic | 1 | 2014 | 75 | 0.110 |
Why?
|
Hepatitis, Viral, Human | 1 | 2014 | 141 | 0.110 |
Why?
|
Treatment Outcome | 10 | 2023 | 64680 | 0.110 |
Why?
|
Middle Aged | 18 | 2024 | 220895 | 0.100 |
Why?
|
Male | 21 | 2024 | 360804 | 0.100 |
Why?
|
Liver Abscess, Pyogenic | 1 | 2012 | 7 | 0.100 |
Why?
|
Liver Abscess, Amebic | 1 | 2012 | 20 | 0.100 |
Why?
|
Diet, Gluten-Free | 1 | 2015 | 283 | 0.100 |
Why?
|
Echinococcosis | 1 | 2012 | 31 | 0.100 |
Why?
|
Tissue and Organ Procurement | 1 | 2021 | 961 | 0.100 |
Why?
|
Esophageal Stenosis | 1 | 2014 | 196 | 0.100 |
Why?
|
Focal Nodular Hyperplasia | 1 | 2012 | 29 | 0.100 |
Why?
|
Adult | 17 | 2024 | 221177 | 0.100 |
Why?
|
Severity of Illness Index | 4 | 2022 | 15842 | 0.100 |
Why?
|
Nucleotides | 1 | 2014 | 454 | 0.100 |
Why?
|
Platelet Count | 1 | 2014 | 781 | 0.100 |
Why?
|
Professional Practice | 1 | 2014 | 313 | 0.100 |
Why?
|
Exercise Therapy | 1 | 2019 | 929 | 0.100 |
Why?
|
Esophagogastric Junction | 1 | 2014 | 347 | 0.100 |
Why?
|
Digestive System Surgical Procedures | 1 | 2017 | 572 | 0.100 |
Why?
|
Hypertension, Portal | 1 | 2014 | 226 | 0.100 |
Why?
|
Endoscopy, Digestive System | 1 | 2014 | 351 | 0.090 |
Why?
|
HIV Infections | 2 | 2014 | 17351 | 0.090 |
Why?
|
Female | 22 | 2024 | 392644 | 0.090 |
Why?
|
Prognosis | 6 | 2024 | 29625 | 0.090 |
Why?
|
Enzymes | 1 | 2011 | 257 | 0.080 |
Why?
|
United States | 6 | 2024 | 72334 | 0.080 |
Why?
|
Patient Selection | 1 | 2021 | 4244 | 0.080 |
Why?
|
Health Policy | 1 | 2021 | 2684 | 0.080 |
Why?
|
Deglutition Disorders | 1 | 2014 | 625 | 0.070 |
Why?
|
Autoantibodies | 2 | 2020 | 2116 | 0.070 |
Why?
|
Antiviral Agents | 2 | 2014 | 3060 | 0.070 |
Why?
|
Chronic Disease | 2 | 2021 | 9318 | 0.070 |
Why?
|
Pregnancy Complications | 1 | 2021 | 2947 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2018 | 2220 | 0.070 |
Why?
|
Decision Trees | 1 | 2009 | 504 | 0.070 |
Why?
|
Celiac Disease | 1 | 2015 | 821 | 0.070 |
Why?
|
Cysts | 1 | 2012 | 681 | 0.070 |
Why?
|
Suicidal Ideation | 1 | 2017 | 1447 | 0.070 |
Why?
|
Survival Rate | 1 | 2021 | 12725 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2020 | 3080 | 0.070 |
Why?
|
Disease Management | 1 | 2017 | 2508 | 0.070 |
Why?
|
Biopsy | 2 | 2021 | 6766 | 0.060 |
Why?
|
Dietary Supplements | 1 | 2019 | 3415 | 0.060 |
Why?
|
Calcium | 1 | 2019 | 5722 | 0.060 |
Why?
|
Aged | 10 | 2024 | 169289 | 0.060 |
Why?
|
Risk Assessment | 3 | 2021 | 23995 | 0.060 |
Why?
|
Vitamin D | 1 | 2019 | 3303 | 0.060 |
Why?
|
Cohort Studies | 7 | 2023 | 41487 | 0.060 |
Why?
|
Time Factors | 2 | 2023 | 39967 | 0.060 |
Why?
|
Prevalence | 3 | 2021 | 15732 | 0.060 |
Why?
|
Immunosuppressive Agents | 2 | 2022 | 4174 | 0.060 |
Why?
|
Uridine | 1 | 2023 | 141 | 0.050 |
Why?
|
Methotrexate | 1 | 2010 | 1719 | 0.050 |
Why?
|
Acute Kidney Injury | 1 | 2015 | 1924 | 0.050 |
Why?
|
Hydrocarbons | 1 | 2023 | 105 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8002 | 0.050 |
Why?
|
Endoscopy | 3 | 2018 | 1851 | 0.050 |
Why?
|
Kynurenine | 1 | 2023 | 141 | 0.050 |
Why?
|
Ribavirin | 1 | 2005 | 395 | 0.050 |
Why?
|
Coronary Artery Disease | 1 | 2021 | 6403 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2024 | 6484 | 0.050 |
Why?
|
Academic Medical Centers | 1 | 2011 | 2759 | 0.040 |
Why?
|
Interferon-alpha | 1 | 2005 | 921 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7390 | 0.040 |
Why?
|
Vibration | 1 | 2022 | 328 | 0.040 |
Why?
|
Fibrosis | 2 | 2021 | 2049 | 0.040 |
Why?
|
Policy | 1 | 2023 | 508 | 0.040 |
Why?
|
Mycophenolic Acid | 1 | 2022 | 348 | 0.040 |
Why?
|
Mice, Inbred NOD | 1 | 2023 | 1827 | 0.040 |
Why?
|
Quality of Life | 2 | 2021 | 13367 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2021 | 15631 | 0.040 |
Why?
|
Antibodies, Antinuclear | 1 | 2020 | 343 | 0.040 |
Why?
|
Ultrasonography | 1 | 2012 | 5972 | 0.040 |
Why?
|
Necrosis | 1 | 2022 | 1611 | 0.040 |
Why?
|
Treatment Failure | 2 | 2018 | 2645 | 0.040 |
Why?
|
Boston | 1 | 2011 | 9326 | 0.040 |
Why?
|
Hepacivirus | 1 | 2005 | 1336 | 0.040 |
Why?
|
Proportional Hazards Models | 2 | 2024 | 12463 | 0.040 |
Why?
|
Living Donors | 1 | 2022 | 641 | 0.040 |
Why?
|
Depression | 1 | 2017 | 8124 | 0.040 |
Why?
|
Octreotide | 1 | 2018 | 153 | 0.040 |
Why?
|
Incidence | 1 | 2015 | 21353 | 0.030 |
Why?
|
Acute Disease | 2 | 2018 | 7237 | 0.030 |
Why?
|
Immunomodulation | 1 | 2020 | 549 | 0.030 |
Why?
|
Sex Factors | 2 | 2020 | 10552 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2014 | 36426 | 0.030 |
Why?
|
Lymphatic Diseases | 1 | 2017 | 320 | 0.030 |
Why?
|
Survival Analysis | 2 | 2019 | 10090 | 0.030 |
Why?
|
Hepatorenal Syndrome | 1 | 2015 | 76 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2020 | 1560 | 0.030 |
Why?
|
Hepatitis B e Antigens | 1 | 2014 | 133 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15266 | 0.030 |
Why?
|
Internationality | 1 | 2019 | 1001 | 0.030 |
Why?
|
Ligands | 1 | 2020 | 3272 | 0.030 |
Why?
|
Guanine | 1 | 2014 | 279 | 0.030 |
Why?
|
Esophageal Diseases | 1 | 2014 | 168 | 0.030 |
Why?
|
Gastrointestinal Agents | 1 | 2018 | 510 | 0.030 |
Why?
|
Lamivudine | 1 | 2014 | 366 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2023 | 2986 | 0.030 |
Why?
|
Drug Discovery | 1 | 2020 | 1051 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2024 | 39106 | 0.020 |
Why?
|
Surgical Instruments | 1 | 2014 | 383 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4853 | 0.020 |
Why?
|
Up-Regulation | 1 | 2020 | 4124 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2921 | 0.020 |
Why?
|
Withholding Treatment | 1 | 2014 | 617 | 0.020 |
Why?
|
Obesity | 2 | 2023 | 12947 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4544 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2021 | 4471 | 0.020 |
Why?
|
alpha-Macroglobulins | 1 | 2009 | 60 | 0.020 |
Why?
|
gamma-Glutamyltransferase | 1 | 2009 | 144 | 0.020 |
Why?
|
Colchicine | 1 | 2010 | 259 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20570 | 0.020 |
Why?
|
Adenine | 1 | 2014 | 987 | 0.020 |
Why?
|
Haptoglobins | 1 | 2009 | 166 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2015 | 1733 | 0.020 |
Why?
|
Apolipoprotein A-I | 1 | 2009 | 299 | 0.020 |
Why?
|
Mitochondria | 1 | 2020 | 3624 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10766 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2021 | 12341 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8830 | 0.020 |
Why?
|
Young Adult | 3 | 2021 | 59243 | 0.010 |
Why?
|
Wounds and Injuries | 1 | 2017 | 2491 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2020 | 18965 | 0.010 |
Why?
|
Inpatients | 1 | 2015 | 2548 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12059 | 0.010 |
Why?
|
Prospective Studies | 2 | 2021 | 54425 | 0.010 |
Why?
|
Patient Readmission | 1 | 2018 | 3270 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2017 | 5294 | 0.010 |
Why?
|
Logistic Models | 1 | 2017 | 13255 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18395 | 0.010 |
Why?
|
Viremia | 1 | 2005 | 707 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 6310 | 0.010 |
Why?
|
Forecasting | 1 | 2009 | 2928 | 0.010 |
Why?
|
Pregnancy | 1 | 2021 | 29874 | 0.010 |
Why?
|
Animals | 2 | 2023 | 168459 | 0.010 |
Why?
|
Polyethylene Glycols | 1 | 2005 | 1189 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 22176 | 0.010 |
Why?
|
Signal Transduction | 1 | 2020 | 23445 | 0.010 |
Why?
|
Mice | 1 | 2023 | 81525 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 88319 | 0.010 |
Why?
|
RNA, Viral | 1 | 2005 | 2846 | 0.010 |
Why?
|
Viral Load | 1 | 2005 | 3332 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2005 | 6534 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2009 | 20098 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2014 | 58976 | 0.000 |
Why?
|
Algorithms | 1 | 2009 | 14031 | 0.000 |
Why?
|
Neoplasms | 1 | 2017 | 22170 | 0.000 |
Why?
|
Concepts
(226)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(35)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_